Nanomedicine-mediated therapies to target breast cancer stem cells

Frontiers in Pharmacology

Volumn 7, Issue SEP, 2016, Pages

  He, Lili ^a   Gu, Jian ^a   Lim, Lee Y ^b   Yuan, Zhi Xiang ^c   Mo, Jingxin ^d  

^a SOUTHWEST UNIVERSITY FOR NATIONALITIES   (China)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c SICHUAN AGRICULTURAL UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

Breast cancer; Breast cancer stem cells; Drug delivery; Nanomedicine; Targeted therapy

Indexed keywords

8 QUINOLINOL; BORTEZOMIB; CHITOSAN; CHLOROQUINE; CURCUMIN; DECITABINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GEMCITABINE DERIVATIVE; HERMES ANTIGEN; HYALURONIC ACID; IRON OXIDE; MACROGOL; NANOCARRIER; NANOTUBE; NAVELBINE; OCTREOTIDE; PACLITAXEL; PHOSPHOLIPID; POLYMER; RETINOIC ACID; SALINOMYCIN; SILICON DIOXIDE; SMALL INTERFERING RNA; THIORIDAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

BREAST CANCER; CANCER STEM CELL; DISEASE MARKER; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PHENOTYPE; REVIEW; TUMOR MICROENVIRONMENT;

EID: 84991790911     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2016.00313     Document Type: Review

References (93)

1. Ahmad, A., Mondal, S. K., Mukhopadhyay, D., Banerjee, R., and Alkharfy, K. M. (2016). Development of liposomal formulation for delivering anticancer drug to breast cancer stem-cell-like cells and its pharmacokinetics in an animal model. Mol. Pharm. 13, 1081-1108. doi: 10.1021/acs.molpharmaceut.5b00900
2. Aires, A., Ocampo, S. M., Sim�es, B. M., Josefa Rodr�guez, M., Cadenas, J. F., Couleaud, P., et al. (2016). Multifunctionalized iron oxide nanoparticles for selective drug delivery to CD44-positive cancer cells. Nanotechnology 27:065103. doi: 10.1088/0957-4484/27/6/065103
3. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., and Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 100, 3983-3988. doi: 10.1073/pnas.0530291100
4. Aomatsu, N., Yashiro, M., Kashiwagi, S., Takashima, T., Ishikawa, T., Ohsawa, M., et al. (2012). CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer. PLoS ONE 7:e45865. doi: 10.1371/journal.pone.0045865
5. Atkinson, R. L., Zhang, M., Diagaradjane, P., Peddibhotla, S., Contreras, A., Hilsenbeck, S. G., et al. (2010). Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci. Trans. Med. 2:55ra79. doi: 10.1126/scitranslmed.3001447
6. Aydin, R. S. (2013). Herceptin-decorated salinomycin-loaded nanoparticles for breast tumor targeting. J. Biomed. Mater. Res. A 101, 1405-1415. doi: 10.1002/jbm.a.34448
7. Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., and Corrie, S. R. (2016). Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm. Res. doi: 10.1007/s11095-016-1958-5 [Epub ahead of print].
8. Bozorgi, A., Khazaei, M., and Khazaei, M. R. (2015). New findings on breast cancer stem cells: a review. J. Breast Cancer 18, 303-312. doi: 10.4048/jbc.2015.18.4.303
9. Brooks, M. D., and Wicha, M. S. (2015). Tumor twitter: cellular communication in the breast cancer stem cell niche. Cancer Discov. 5, 469-471. doi: 10.1158/2159-8290
10. Burke, A. R., Singh, R. N., Carroll, D. L., Wood, J. C., D'Agostino, R. B. Jr., Ajayan, P. M., et al. (2012). The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy. Biomaterials 33, 2961-2970. doi: 10.1016/j.biomaterials.2011.12.052
11. Carrasco, E., Alvarez, P. J., Prados, J., Melguizo, C., Rama, A. R., Ar�nega, A., et al. (2014). Cancer stem cells and their implication in breast cancer. Eur. J. Clin. Invest. 44, 678-687. doi: 10.1111/eci.12276
12. Chapellier, M., and Maguer-Satta, V. (2016). BMP2, a key to uncover luminal breast cancer origin linked to pollutant effects on epithelial stem cells niche. Mol. Cell. Oncol. 3:e1026527. doi: 10.1080/23723556.2015.1026527
13. Chen, D., Bhat-Nakshatri, P., Goswami, C., Badve, S., and Nakshatri, H. (2013). ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer. Cancer Res. 73, 5821-5833. doi: 10.1158/0008-5472.CAN-13-1080
14. Chen, D., Wang, G., Song, W., and Zhang, Q. (2015). Novel CD44 receptor targeting multifunctional "nano-eggs" based on double pH-sensitive nanoparticles for co-delivery of curcumin and paclitaxel to cancer cells and cancer stem cells. J. Nanopart. Res. 17:421. doi: 10.1007/s11051-015-3217-9
15. Chen, H., Wang, Y., Wang, T., Shi, D., Sun, Z., Xia, C., et al. (2016). Application prospective of nanoprobes with MRI and FI dual-modality imaging on breast cancer stem cells in tumor. J. Nanobiotechnol. 14:52. doi: 10.1186/s12951-016-0195-8
16. Clarke, M. F. (2005). A self-renewal assay for cancer stem cells. Cancer Chemother. Pharmacol. 56(Suppl. 1), 64-68. doi: 10.1007/s00280-005-0097-1
17. Croker, A. K., and Allan, A. L. (2012). Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells. Breast Cancer Res. Treat. 133, 75-87. doi: 10.1007/s10549-011-1692-y
18. Dick, J. E. (2003). Breast cancer stem cells revealed. Proc. Natl. Acad. Sci. U.S.A. 100, 3547-3549. doi: 10.1073/pnas.0830967100
19. Dontu, G., Al-Hajj, M., Abdallah, W. M., Clarke, M. F., and Wicha, M. S. (2003). Stem cells in normal breast development and breast cancer. Cell Prolif. 36(Suppl. 1), 59-72. doi: 10.1046/j.1365-2184.36.s.1.6.x
20. Dontu, G., El-Ashry, D., and Wicha, M. S. (2004). Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol. Metab. 15, 193-197. doi: 10.1016/j.tem.2004.05.011
21. Estanqueiro, M., Amaral, M. H., Concei��o, J., and Sousa Lobo, J. M. (2015). Nanotechnological carriers for cancer chemotherapy: the state of the art. Colloids Surf. B Biointerfaces 126, 631-648. doi: 10.1016/j.colsurfb.2014.12.041
22. Ganesh, S., Iyer, A. K., Morrissey, D. V., and Amiji, M. M. (2013). Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials 34, 3489-3502. doi: 10.1016/j.biomaterials.2013.01.077
23. Gao, Y., Xie, J., Chen, H., Gu, S., Zhao, R., Shao, J., et al. (2014). Nanotechnology-based intelligent drug design for cancer metastasis treatment. Biotechnol. Adv. 3, 761-777. doi: 10.1016/j.biotechadv.2013.10.013
24. Gener, P., Gouveia, L. P., Sabat, G. R., de Sousa Rafael, D. F., Fort, N. B., Arranja, A., et al. (2015). Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells. Nanomedicine 11, 1883-1892. doi: 10.1016/j.nano.2015.07.009
25. Geng, S. Q., Alexandrou, A. T., and Li, J. J. (2014). Breast cancer stem cells: multiple capacities in tumor metastasis. Cancer Lett. 349, 1-7. doi: 10.1016/j.canlet.2014.03.036
26. Ginestier, C., Hur, M. H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., et al. (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-567. doi: 10.1016/j.stem.2007.08.014
27. Ginestier, C., Liu, S., Diebel, M. E., Korkaya, H., Luo, M., Brown, M., et al. (2010). CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest. 120, 485-497. doi: 10.1172/JCI39397
28. G�tte, M., and Yip, G. W. (2006). Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res. 66, 10233-10237. doi: 10.1158/0008-5472.CAN-06-1464
29. G�l��r, E., Thaqi, M., Khaja, F., Kuzmis, A., and Ony�ksel, H. (2013). Curcumin in VIP-targeted sterically stabilized phospholipid nanomicelles: a novel therapeutic approach for breast cancer and breast cancer stem cells. Drug Deliv. Transl. Res. 3:10. doi: 10.1007/s13346-013-0167-6
30. Guo, W., Keckesova, Z., Donaher, J. L., Shibue, T., Tischler, V., Reinhardt, F., et al. (2012). Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148, 1015-1028. doi: 10.1016/j.cell.2012.02.008
31. Hu, K., Law, J. H., Fotovati, A., and Dunn, S. E. (2012). Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells. Breast Cancer Res. 14:R22. doi: 10.1186/bcr3107
32. Jeong, K., Kang, C. S., Kim, Y., Lee, Y. D., Kwon, I. C., and Kim, S. (2016). Development of highly efficient nanocarrier-mediated delivery approaches for cancer therapy. Cancer Lett. 374, 31-43. doi: 10.1016/j.canlet.2016.01.050
33. Ke, X. Y., Lin Ng, V. W., Gao, S. J., Tong, Y. W., Hedrick, J. L., and Yang, Y. Y. (2014). Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells. Biomaterials 35, 1096-1108. doi: 10.1016/j.biomaterials.2013.10.049
34. Kesharwani, R. K., Srivastava, V., Singh, P., Rizvi, S. I., Adeppa, K., and Misra, K. (2015). A novel approach for overcoming drug resistance in breast cancer chemotherapy by targeting new synthetic curcumin analogues against aldehyde dehydrogenase 1 (ALDH1A1) and glycogen synthase kinase-3 β (GSK-3β). Appl. Biochem. Biotechnol. 176, 1996-2017. doi: 10.1007/s12010-015-1696-x
35. Keysar, S. B., and Jimeno, A. (2010). More than markers: biological significance of cancer stem cell-defining molecules. Mol. Cancer Ther. 9, 2450-2457. doi: 10.1158/1535-7163.MCT-10-0530
36. Kievit, F. M., and Zhang, M. (2011). Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biologicalbarriers. Adv. Mater. 23, 217-247. doi: 10.1002/adma.201102313
37. Kim, Y. J., Liu, Y., Li, S., Rohrs, J., Zhang, R., Zhang, X., et al. (2015). Co-eradication of breast cancer cells and cancer stem cells by cross-linked multilamellar liposomes enhances tumor treatment. Mol. Pharm. 12, 2811-2822. doi: 10.1021/mp500754r
38. Koren, S., Reavie, L., Couto, J. P., De Silva, D., Stadler, M. B., Roloff, T., et al. (2015). PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. Nature 525, 114-118. doi: 10.1038/nature14669
39. Korkaya, H., Kim, G. I., Davis, A., Malik, F., Henry, N. L., Ithimakin, S., et al. (2012). Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol. Cell 47, 570-584. doi: 10.1016/j.molcel.2012.06.014
40. Korkaya, H., Liu, S., and Wicha, M. S. (2011). Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. Clin. Cancer Res. 17, 6125-6129. doi: 10.1158/1078-0432.CCR-10-2743
41. LaBarge, M. A. (2010). The difficulty of targeting cancer stem cell niches. Clin. Cancer Res. 16, 3121-3129. doi: 10.1158/1078-0432.CCR-09-2933
42. Li, R. J., Ying, X., Zhang, Y., Ju, R. J., Wang, X. X., Yao, H. J., et al. (2011). All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. J. Control. Release 149, 281-291. doi: 10.1016/j.jconrel.2010.10.019
43. Li, S. Y., Sun, R., Wang, H. X., Shen, S., Liu, Y., Du, X. J., et al. (2015). Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells. J. Control. Release 205, 7-14. doi: 10.1016/j.jconrel.2014.11.011
44. Liang, D. H., Choi, D. S., Ensor, J. E., Kaipparettu, B. A., Bass, B. L., and Chang, J. C. (2016). The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair. Cancer Lett. 376, 249-258. doi: 10.1016/j.canlet.2016.04.002
45. Liu, S., Dontu, G., and Wicha, M. S. (2005). Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res. 7, 86-95. doi: 10.1186/bcr1021
46. Liu, Y., Lu, W. L., Guo, J., Du, J., Li, T., Wu, J. W., et al. (2008). A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. J. Control. Release 129, 18-25. doi: 10.1016/j.jconrel.2008.03.022
47. Lohberger, B., Rinner, B., Stuendl, N., Absenger, M., Liegl-Atzwanger, B., Walzer, S. M., et al. (2012). Aldehyde dehydrogenase 1, a potential marker for cancer stem cells in human sarcoma. PLoS ONE 7:e43664. doi: 10.1371/journal.pone.0043664
48. Lu, B., Huang, X., Mo, J., and Zhao, W. (2016). Drug delivery using nanoparticles for cancer stem-like cell targeting. Front. Pharmacol. 7:84. doi: 10.3389/fphar.2016.00084
49. Masood, F. (2016). Polymeric nanoparticles for targeted drug delivery system for cancer therapy. Mater. Sci. Eng. C Mater. Biol. Appl. 60, 569-578. doi: 10.1016/j.msec.2015.11.067
50. Meyer, M. J., Fleming, J. M., Lin, A. F., Hussnain, S. A., Ginsburg, E., and Vonderhaar, B. K. (2010). CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptornegative breast cancer. Cancer Res. 70, 4624-4633. doi: 10.1158/0008-5472.CAN-09-3619
51. Mine, T., Matsueda, S., Li, Y., Tokumitsu, H., Gao, H., Danes, C., et al. (2009). Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells. Cancer Immunol. Immunother. 58, 1185-1194. doi: 10.1007/s00262-008-0623-1
52. Mizrak, D., Brittan, M., and Alison, M. (2008). CD133: molecule of the moment. J. Pathol. 214, 3-9. doi: 10.1002/path.2283
53. Moncharmont, C., Levy, A., Gilormini, M., Bertrand, G., Chargari, C., Alphonse, G., et al. (2012). Targeting a cornerstone of radiation resistance: cancer stem cell. Cancer Lett. 322, 139-147. doi: 10.1016/j.canlet.2012.03.024
54. Muntimadugu, E., Kumar, R., Saladi, S., Rafeeqi, T. A., and Khan, W. (2016). CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel. Colloids Surf. B Biointerfaces 143, 532-546. doi: 10.1016/j.colsurfb.2016.03.075
55. Narayan, M., Wilken, J. A., Harris, L. N., Baron, A. T., Kimbler, K. D., and Maihle, N. J. (2009). Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res. 69, 2191-2194. doi: 10.1158/0008-5472.CAN-08-1056
56. Paholak, H. J., Stevers, N. O., Chen, H., Burnett, J. P., He, M., Korkaya, H., et al. (2016). Elimination of epithelial-like and mesenchymal-like breast cancer stem cells to inhibit metastasis following nanoparticle-mediated photothermal therapy. Biomaterials 104, 145-157. doi: 10.1016/j.biomaterials.2016.06.045
57. Park, S. Y., Lee, H. E., Li, H., Shipitsin, M., Gelman, R., and Polyak, K. (2010). Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin. Cancer Res. 16, 876-887. doi: 10.1158/1078-0432.CCR-09-1532
58. Park, W., Yang, H. N., Ling, D., Yim, H., Kim, K. S., Hyeon, T., et al. (2014). Multi-modal transfection agent based on monodisperse magnetic nanoparticles for stem cell gene delivery and tracking. Biomaterials 35, 7239-7247. doi: 10.1016/j.biomaterials.2014.05.010
59. Passegu�, E., Jamieson, C. H., Ailles, L. E., and Weissman, I. L. (2003). Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc. Natl. Acad. Sci. U.S.A. 100(Suppl. 1), 11842-11849. doi: 10.1073/pnas.2034201100
60. Polyak, K. (2007). Breast cancer: origins and evolution. J. Clin. Invest. 117, 3155-3163. doi: 10.1172/JCI33295
61. Ponti, D., Costa, A., Zaffaroni, N., Pratesi, G., Petrangolini, G., Coradini, D., et al. (2005). Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 65, 5506-5511. doi: 10.1158/0008-5472.CAN-05-0626
62. Rao, W., Wang, H., Han, J., Zhao, S., Dumbleton, J., Agarwal, P., et al. (2015). Chitosan-decorated doxorubicin-encapsulated nanoparticle targets and eliminates tumor reinitiating cancer stem-like cells. ACS Nano 9, 5725-5740. doi: 10.1021/nn506928p
63. Ricardo, S., Vieira, A. F., Gerhard, R., Leit�o, D., Pinto, R., Cameselle-Teijeiro, J. F., et al. (2011). Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J. Clin. Pathol. 64, 937-946. doi: 10.1136/jcp.2011.090456
64. Sadhukha, T., Niu, L., Wiedmann, T. S., and Panyam, J. (2013). Effective elimination of cancer stem cells by magnetic hyperthermia. Mol. Pharmaceutics 10, 1432-1441. doi: 10.1021/mp400015b
65. Shen, S., Du, X. J., Liu, J., Sun, R., Zhu, Y. H., and Wang, J. (2015). Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy. J. Control. Release 208, 14-24. doi: 10.1016/j.jconrel.2014.12.043
66. Shen, S., Xia, J. X., and Wang, J. (2016). Nanomedicine-mediated cancer stem cell therapy. Biomaterials 74, 1-18. doi: 10.1016/j.biomaterials.2015.09.037
67. Soni, G., and Yadav, K. S. (2016). Nanogels as potential nanomedicine carrier for treatment of cancer: a mini review of the state of the art. Saudi Pharm. J. 24, 133-139. doi: 10.1016/j.jsps.2014.04.001
68. Subramaniam, D., Ramalingam, S., Houchen, C. W., and Anant, S. (2010). Cancer stem cells: a novel paradigm for cancer prevention and treatment. Mini Rev. Med. Chem. 10, 359-371. doi: 10.2174/138955710791330954
69. Sun, R., Liu, Y., Li, S. Y., Shen, S., Du, X. J., Xu, C. F., et al. (2015). Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells. Biomaterials 37, 405-414. doi: 10.1016/j.biomaterials.2014.10.018
70. Sun, R., Shen, S., Zhang, Y. J., Xu, C. F., Cao, Z. T., Wen, L. P., et al. (2016). Nanoparticle facilitated autophagy inhibition promotes the efficacy of chemotherapeutics against breast cancer stem cells. Biomaterials 103, 44-55. doi: 10.1016/j.biomaterials.2016.06.038
71. Sun, T. M., Wang, Y. C., Wang, F., Du, J. Z., Mao, C. Q., Sun, C. Y., et al. (2014). Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds. Biomaterials 35, 836-845. doi: 10.1016/j.biomaterials.2013.10.011
72. Sung, C. K., Hong, K. A., Lin, S., Lee, Y., Cha, J., Lee, J. K., et al. (2009). Dual-modal nanoprobes for imaging of mesenchymal stem cell transplant by MRI and fluorescence imaging. Korean J. Radiol. 10, 613-622. doi: 10.3348/kjr.2009.10.6.613
73. Swaminathan, S. K., Roger, E., Toti, U., Niu, L., Ohlfest, J. R., and Panyam, J. (2013). CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J. Control. Release 171, 280-287. doi: 10.1016/j.jconrel.2013.07.014
74. Torchilin, V. P. (2007). Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 24, 1-16. doi: 10.1007/s11095-006-9132-0
75. Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., and Jemal, A. (2015). Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87-108. doi: 10.3322/caac.21262
76. Tran, T. A., Krishnamoorthy, K., Cho, S. K., and Kim, S. J. (2016). Inhibitory effect of zinc sulfide nanoparticles towards breast cancer stem cell migration and invasion. J. Biomed. Nanotechnol. 12, 329-336. doi: 10.1166/jbn.2016.2187
77. Vinogradov, S., and Wei, X. (2012). Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond) 7, 597-615. doi: 10.2217/nnm.12.22
78. Vira, D., Basak, S. K., Veena, M. S., Wang, M. B., Batra, R. K., and Srivatsan, E. S. (2012). Cancer stem cells, microRNAs, and therapeutic strategies including natural products. Cancer Metastasis Rev. 31, 733-751. doi: 10.1007/s10555-012-9382-8
79. Vuu, K., Xie, J., McDonald, M. A., Bernardo, M., Hunter, F., Zhang, Y., et al. (2005). Gadolinium-rhodamine nanoparticles for cell labeling and tracking via magnetic resonance and optical imaging. Bioconjugate Chem. 16, 995-999. doi: 10.1021/bc050085z
80. Wang, D., Huang, J., Wang, X., Yu, Y., Zhang, H., Chen, Y., et al. (2013). The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel. Biomaterials 34, 7662-7673. doi: 10.1016/j.biomaterials.2013.06.042
81. Wang, X. Y., Penalva, L. O., Yuan, H., Linnoila, R. I., Lu, J., Okano, H., et al. (2010). Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival. Mol. Cancer 9:221. doi: 10.1186/1476-4598-9-221
82. Wei, X., Senanayake, T. H., Warren, G., and Vinogradov, S. V. (2013). Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors. Bioconjugate Chem. 24, 658-668. doi: 10.1021/bc300632w
83. Wicha, M. S., Dontu, G., Al-Hajj, M., and Clarke, M. F. (2003). Stem cells in normal breast development and breast cancer. Breast Cancer Res. 5(Suppl. 1), 59-72. doi: 10.1186/bcr709
84. Williams, C., Helguero, L., Edvardsson, K., Haldos�n, L. A., and Gustafsson, J. A. (2009). Gene expression in murine mammary epithelial stem cell-like cells shows similarities to human breast cancer gene expression. Breast Cancer Res. 11:R26. doi: 10.1186/bcr2256
85. Xu, C., and Wang, J. (2015). Delivery systems for siRNA drug development in cancer therapy. Asian J. Pharm. Sci. 10, 1-12. doi: 10.1016/j.ajps.2014.08.011
86. Xu, Y., Wang, J., Li, X., Liu, Y., Dai, L., Wu, X., et al. (2014). Selective inhibition of breast cancer stem cells by gold nanorods mediated plasmonic hyperthermia. Biomaterials 35, 4667-4677. doi: 10.1016/j.biomaterials.2014.02.035
87. Yip, N. C., Fombon, I. S., Liu, P., Brown, S., Kannappan, V., Armesilla, A. L., et al. (2011). Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br. J. Cancer 104, 1564-1574. doi: 10.1038/bjc.2011.126
88. Zhang, Y., Zhang, H., Wang, X., Wang, J., Zhang, X., and Zhang, Q. (2012). The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials 33, 679-691. doi: 10.1016/j.biomaterials.2011.09.072
89. Zhao, P., Dong, S., Bhattacharyya, J., and Chen, M. (2014). iTEP nanoparticle-delivered salinomycin displays an enhanced toxicity to cancer stem cells in orthotopic breast tumors. Mol. Pharm. 11, 2703-2712. doi: 10.1021/mp5002312
90. Zhao, P., Lu, Y., Jiang, X., and Li, X. (2011). Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci. 102, 1107-1111. doi: 10.1111/j.1349-7006.2011.01894.x
91. Zhao, Y., Alakhova, D. Y., and Kabanov, A. V. (2013). Can nanomedicines kill cancer stem cells? Adv. Drug Deliv. Rev. 6, 1763-1783. doi: 10.1016/j.addr.2013.09.016
92. Zobalova, R., McDermott, L., Stantic, M., Prokopova, K., Dong, L. F., and Neuzil, J. (2008). CD133-positive cells are resistant to TRAIL due to up-regulation of FLIP. Biochem. Biophys. Res. Commun. 373, 567-571. doi: 10.1016/j.bbrc.2008.06.073
93. Zuo, Z. Q., Chen, K. G., Yu, X. Y., Zhao, G., Shen, S., Cao, Z. T., et al. (2016). Promoting tumor penetration of nanoparticles for cancer stem cell therapy by TGF-β signaling pathway inhibition. Biomaterials 82, 48-59. doi: 10.1016/j.biomaterials.2015.12.014